Co-Delivery of Silymarin and Metformin Dual-Loaded in Mesoporous Silica Nanoparticles Synergistically Sensitizes Breast Cancer Cell Line to Mitoxantrone Chemotherapy

Harandi, Zahra Rezaei; Heidari, Razieh; Reiisi, Somayeh

doi:10.1109/tnb.2023.3242912

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The coloaded MSNPs significantly inhibited breast cancer resistance protein (BCRP) mRNA expression, promoting apoptosis in MCF-7 cells. 111 Therefore, the finding concludes that both SLM and Met’s anticancer effects enhance the anticancer effect against BC. Recently, researchers developed CUR-loaded amine-functionalized MSNPs, which revealed high drug loading efficiency with sustained release when tested against MCF-7 cells.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 86%

“…In vitro cytotoxicity studies showed lower IC 50 values for Met-MSNPs, SLM-MSNPs, and dual drug MSNPs than free-Met, free-SLM, and free-Met-SLM. The coloaded MSNPs significantly inhibited breast cancer resistance protein (BCRP) mRNA expression, promoting apoptosis in MCF-7 cells . Therefore, the finding concludes that both SLM and Met’s anticancer effects enhance the anticancer effect against BC.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Rahman,

Afzal,

Ullah

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Breast cancer (BC) is a malignant neoplasm that begins in the breast tissue. After skin cancer, BC is the second most common type of cancer in women. At the end of 2040, the number of newly diagnosed BC cases is projected to increase by over 40%, reaching approximately 3 million worldwide annually. The hormonal and chemotherapeutic approaches based on conventional formulations have inappropriate therapeutic effects and suboptimal pharmacokinetic responses with nonspecific targeting actions. To overcome such issues, the use of nanomedicines, including liposomes, nanoparticles, micelles, hybrid nanoparticles, etc., has gained wider attention in the treatment of BC. Smaller dimensional nanomedicine (especially 50–200 nm) exhibited improved in vivo effectiveness, such as better tissue penetration and more effective tumor suppression through enhanced retention and permeation, as well as active targeting of the drug. Additionally, nanotechnology, which further extended and developed theranostic nanomedicine by incorporating diagnostic and imaging agents in one platform, has been applied to BC. Furthermore, hybrid and theranostic nanomedicine has also been explored for gene delivery as anticancer therapeutics in BC. Moreover, the nanocarriers’ size, shape, surface charge, chemical compositions, and surface area play an important role in the nanocarriers’ stability, cellular absorption, cytotoxicity, cellular uptake, and toxicity. Additionally, nanomedicine clinical translation for managing BC remains a slow process. However, a few cases are being used clinically, and their progress with the current challenges is addressed in this Review. Therefore, this Review extensively discusses recent advancements in nanomedicine and its clinical challenges in BC.

show abstract

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 86%

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Rahman,

Afzal,

Ullah

et al. 2023

ACS Omega

View full text Add to dashboard Cite

show abstract

Hippophae Rhamnoides‐derived Phytomedicine Nano‐System Modulates Bax/Fas Pathways to Reduce Proliferation in Triple‐Negative Breast Cancer

Farheen,

Iqbal,

Mushtaq

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Triple‐negative breast cancer (TNBC) is the most common primary tumor of the breast with limited effectual drug availability. Therefore, the aim of the study is to develop an innovative phyto‐nanomedicine (PNM) to cure TNBC with the least genotoxicity. Hereinafter, the sea buckthorn’ extracted polyphenols (SBP), combine with metformin (MET), are synthesized as a novel PNM to evaluate its anti‐tumor properties, effectiveness, and mechanism of action in TNBC in vitro and in vivo models. The SBP exhibits 16 new kinds of polyphenols that are been reported earlier which regulated cell development, proliferation, and programmed cell death (PCD) effectively. SBP‐MET PNM inhibits MDA‐MB‐231 (47%), MDA‐MB‐436 (46%), and 4T1 (46%) cell proliferation but does not affect L929 normal murine cell development and successfully induce PCD (73.19%) in MDA‐MB‐231 cells. Mechanistically, in vivo SBP‐MET proteome expression profiling reveals upregulation of proapoptotic Bax protein and activation of Fas signaling pathways convince downstream Daxx and FADD proteins, which further triggers Caspase‐3 that prompts apoptosis in human TNBC cells by cleaving PARP‐1 protein. Current findings establish innovative highly biocompatible phyto‐nanomedicine that has significant potential to inhibit TNBC cell growth and induce regulated cell death (RCD) in vivo model, thereby opening a new arena for TNBC therapy.

show abstract

Recent advances in mesoporous silica nanoparticles formulations and drug delivery for wound healing

Heidari,

Assadollahi,

Shakib Manesh

et al. 2024

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Co-Delivery of Silymarin and Metformin Dual-Loaded in Mesoporous Silica Nanoparticles Synergistically Sensitizes Breast Cancer Cell Line to Mitoxantrone Chemotherapy

Cited by 3 publications

References 32 publications

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Hippophae Rhamnoides‐derived Phytomedicine Nano‐System Modulates Bax/Fas Pathways to Reduce Proliferation in Triple‐Negative Breast Cancer

Recent advances in mesoporous silica nanoparticles formulations and drug delivery for wound healing

Contact Info

Product

Resources

About